ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Are we too late on our Covid serology test?

<< Previous

Bullboard Posts

Next >>

Post by retiredcopon Sep 02, 2021 8:20am

220 Views

Post# 33799788

Are we too late on our Covid serology test?

I find it interesting that people I talk with and what people,post....for some reason some think that PMN was too slow or too late in bringing their covid serology test to market ...we may want to reconsider that opinion....

Coronavirus variants of interest

Variant of interest	World Health Organization label	Earliest documented samples	Date of designation
B.1.525	Eta	Multiple countries, December 2020	March 17, 2021
B.1.526	Iota	United States of America, November 2020	March 24, 2021
B.1.617.1	Kappa	India, October 2020	April 4, 2021
C.37	Lambda	Peru, December 2020	June 14, 2021
B.1.621	Mu	Colombia, January 2021	August 30, 2021